Announcements Trials
Browse Landscape

Phase

Phase NA 114Phase 1 57Phase 2 55Phase 1/2 28Phase 3 21Phase 2/3 6Phase EARLY_PHASE1 5Phase 4 3

Status

Recruiting 5Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 8Neoplasms 6Stomach Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Oropharyngeal Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Fatigue 4Urinary Bladder Neoplasms 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Myasthenia Gravis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Weight Loss 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2

Interventions

osimertinib 1Surgical Procedures, Operative 1Standard of Care 1Sildenafil Citrate 1Radiotherapy 1Pemetrexed 1Immunotherapy 1Drug Therapy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasms × 30 days × Clear all
NCT07005102 2026-05-22

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

AbbVie

Phase 2/3 Recruiting
854 enrolled
Tumor-Agnostic

Neoplasms

NCT06989437 2026-05-20

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Pfizer

Phase 2/3 Recruiting
982 enrolled
Gastrointestinal

Anorexia, Cachexia, Fatigue, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Weight Loss

NCT07112196 2026-05-20

VINCIT

CatalYm GmbH

Phase 2/3 Recruiting
518 enrolled

Anorexia, Cachexia, Neoplasms, Weight Loss

NCT06800092 2026-05-11

SPARC

The University of Texas Medical Branch, Galveston

Phase 2/3 Not yet recruiting
30 enrolled

Fatigue, Mental Fatigue, Neoplasms

NCT07000253 2026-05-07

OMEC-5

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2/3 Recruiting
290 enrolled
Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT06085716 2026-05-05

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
240 enrolled

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡